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Case 1
A 21-year-old HIV-infected woman with a CD4 count of 215 cells/µL, 
who was on unidentified antiretroviral (ARV) treatment, presented 
to her local district hospital, having ingested 70 rifampicin (150 mg)/
isoniazid (INH) (75 mg) combination tablets for continuation-phase 
treatment of tuberculosis (TB). No specific therapy was given. She 
was fully conscious on days 1 and 2, but had a Glascow coma scale 
(GCS) score of 7/15 on day 3. No seizures were observed. On the 
day of her arrival at our institution, her GCS score was 6/15 and she 
was intubated and ventilated in the intensive care unit (ICU). The 
patient had a compensated metabolic acidosis on analysis of arterial 
blood (standard bicarbonate 18 mmol/L), but the lactate level was 
not measured. On admission, her serum creatinine was 254 μmol/L, 
but it normalised within 3 days. Pyridoxine 5 g was administered via 
a nasogastric tube (NGT), but with no response in her level of con-
sciousness. She spent almost 4 months in the ICU, without any neu-
rological recovery, and died shortly after transfer to a general ward.
Case 2 
A 32-year-old HIV-infected woman, who was receiving tenofovir/emtri-
citabine/efavirenz fixed-dose combination ARVs, and 300 mg INH daily 
as INH preventive therapy (IPT), was found unconscious with two empty 
bottles of each of the abovementioned agents. She suffered multiple 
seizures while being transferred to our hospital, was assessed as being 
in status epilepticus on arrival, and required 60 mg diazepam and 
a phenytoin loading dose to terminate her seizures. She suffered a 
cardiorespiratory arrest, and was resuscitated, intubated and venti-
lated in the ICU. Once the INH ingestion was recognised, 5 g pyridoxine 
was administered via an NGT. Her arterial blood lactate level was 
15.3 mmol/L, and her serum creatinine 220 μmol/L, both of which 
normalised with supportive care. A computed tomography (CT) scan 
of her brain was normal. Her GCS improved from 3/15 to 7/15 by 
day 10, but failed to recover further. On day 31 she was transferred 
to a general ward and died.
Case 3
A 52-year-old HIV-infected woman, with a CD4 count of 274 cells/µL, 
was found unconscious with empty tenofovir/emtricitabine/efavirenz 
fixed-dose combination ARVs and IPT containers. She was also 
heavily intoxicated with ethanol. She arrived at the hospital in 
status epilepticus, her seizures were refractory to clonazepam and 
a phenytoin loading dose infusion, but her convulsions decreased 
during a propofol infusion in the ICU. There was a 48-hour delay 
before INH toxicity was recognised as the possible cause of her seizures; 
5 g pyridoxine was then administered via an NGT, after which she expe-
rienced no further seizures. Her arterial lactate was 16.6 mmol/L and 
serum creatine kinase 41 015 U/L. She developed acute renal failure, 
requiring 7 days of haemodialysis, after which her renal function 
recovered fully. A CT scan of her brain was normal. She was extubated 
after 11 days, and continued to full recovery after almost 4 weeks.
Discussion
INH, the hydrazide of isonicotinic acid, has been the mainstay of 
TB treatment and prevention since the 1950s. Most clinicians are 
familiar with the common side-effects of peripheral neuropathy and 
hepatotoxicity, but lesser known, severe INH toxicity is characterised by 
recurrent seizures, lactic acidosis, coma and death. As little as 1.5 g INH 
has been reported to cause mild toxicity, doses of 6 - 10 g may result in 
severe toxicity, while doses >15 g may be fatal.[1] 
INH is rapidly absorbed, reaching peak levels in 1 - 2 hours, with 
minimal protein binding. It is metabolised in the liver by polymorphic 
acetylation, with a half-life of between 1 and 4 hours, varying between 
fast and slow acetylators. INH exerts toxicity by inhibiting pyridoxine 
kinase, the enzyme responsible for the production of pyridoxal 
phos phate, the active form of pyridoxine. Pyridoxal phosphate is 
a co-factor in the synthesis of gamma-aminobutyric acid (GABA), 
a major inhibitory neurotransmitter.[1] Consequently, INH toxicity 
leads to reduced GABA, which can induce seizures. Lactic acidosis is 
thought to occur by INH inhibition of lactate dehydrogenase via its 
effect on the co-enzyme nicotinamide adenine dinucleotide. This is 
exacerbated by increased lactate production during seizures.
For the management of an INH overdose, after initial stabilisation, 
gastric lavage is indicated within 1 hour of INH ingestion. This can 
be followed by charcoal administration, which can be given with 
sorbitol,[2] concurrently with the prompt administration of high 
doses of pyridoxine, preferably as an intravenous preparation, but as 
crushed tablets via an NGT if the former is unavailable. Most authors 
recommend a mass equivalent dose according to the amount of INH 
ingested, if known. This was shown to have superior seizure control 
in a case series of five patients compared with 41 cases reported in 
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the literature, where other approaches were used.[3] If the ingested 
dose is unknown, 70 mg/kg pyridoxine is recommended, up to a total 
of 5 g.[1] This alone may be enough to terminate seizures, but if not, 
benzodiazepines are the preferred anticonvulsant. Animal studies 
have demonstrated synergy between pyridoxine and diazepam 
(a GABAA, benzodiazepine-site agonist) in reducing INH-induced 
seizures, but not with phenytoin (a sodium channel antagonist).[1] 
Haemodialysis will eliminate INH, but it is generally not required, 
except in the most severe cases that do not respond to pyridoxine. 
Based on the half-life of INH, it should be used early to obtain an 
optimal effect.[1] 
Notably, all three of our patients developed acute renal failure, 
one requiring dialysis, but renal function recovered in all. This has 
only been described in one other INH toxicity case report, where 
INH was combined with rifampicin.[4] Two, and possibly all three 
patients, co-ingested unknown amounts of tenofovir-containing fixed-
dose combination tablets. Even though tenofovir is known to cause 
nephrotoxicity over time in therapeutic doses, no cases of acute renal 
failure have been reported with an overdose.[5] Case 3 had a high 
creatine kinase level, presumably caused by seizure-induced rhabdo-
myolysis, which may have contributed to acute tubular necrosis. 
From a public health perspective, our concern is that severe INH 
overdose cases are likely to become more frequent following the 
recent roll-out of IPT for HIV-positive adults in South Africa (SA). 
INH is now available as a 300 mg tablet (previously 100 mg or a maxi-
mum of 150 mg in combination with rifampicin), giving a total dose 
of 8.4 g in a month’s supply (well into the range of severe toxicity). 
IPT is administered for long periods (6 - 36 months), and potentially 
most of SA’s estimated 6.5 million HIV-infected adults qualify to 
receive it.[6] While the benefits of IPT in preventing TB are clear, we 
believe clinicians need to be aware of the risk of INH overdose, and 
be cautious when considering IPT for patients with suicidal risks. 
HIV-positive patients have a high level of suicidal ideation (up to 83% 
in a recent post-voluntary testing and counselling study in KwaZulu-
Natal[7]), and there is evidence that efavirenz may further increase the 
risk of suicidality.[8]
Emergency clinicians need to have a high index of suspicion 
for INH overdose in patients presenting with resistant status epi-
lepticus or unexplained lactic acidosis, and be familiar with the 
emergency management, as discussed above. The registration and 
supply of intravenous pyridoxine, and the availability of laborato-
ries determining INH levels, would also assist in better managing 
suspected cases.
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